At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Morgan Roupret, MD, of Hopital Pitié-Salpétrière, and Nadine Houede, MD, of Montpellier University, dissect their research on the safety and efficacy of neoadjuvant immunotherapy with durvalumab in combination with neoadjuvant gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma.
Durvalumab With NAC in Patients With Operable High-Risk UTUC
By Morgan Roupret, MD, Nadine Houede, MD - Last Updated: February 24, 2025Related Posts
Dr. Murray and Laura Bauer share their experiences treating patients with UTUC using mitomycin gel.
Patients who achieved a complete response after six doses of UGN-101 were followed up for 12 months after initial CR.
Dr. Hafron breaks down the most important updates in upper tract urothelial carcinoma from the LUGPA 2024 Annual Meeting.
Drs. Michael Whalen and Vincent Xu discuss potential alternative treatments for patients who are ineligible for chemotherapy.
Drs. Michael Whalen and Vincent Xu discuss their recent analysis of neoadjuvant chemotherapy utilization for UTUC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.